Supreme Court Maintains Mail Access to Abortion Pill Amid Ongoing Legal Battle
The U.S. Supreme Court has temporarily preserved nationwide access to mifepristone, allowing its distribution via mail and telehealth, as legal proceedings continue.
The U.S. Supreme Court has temporarily preserved nationwide access to mifepristone, a key drug used in medication abortions, while legal proceedings continue. The court blocked a lower court ruling that would have restricted access to the drug, including banning mail delivery and requiring in-person doctor visits.
The decision supports the FDA's existing rules, which have allowed telehealth prescriptions and pharmacy sales since 2021. This ruling comes amid ongoing legal challenges from anti-abortion groups and a lawsuit filed by Louisiana, asserting the FDA's approval undermines the state’s abortion ban and questions the drug’s safety.
Justices Clarence Thomas and Samuel Alito dissented, with Alito accusing drug makers of profiting unlawfully in states with abortion bans. The case reflects the continued national debate over abortion access following the 2022 overturning of Roe v. Wade. While this ruling maintains the current status quo, further decisions are expected as the case proceeds, possibly returning to the Supreme Court.
The Biden administration has remained mostly silent on this issue, balancing its stance amid competing political pressures. Mifepristone remains widely used, accounting for nearly two-thirds of U.S. abortions as of 2023.